Form 4: Pliant Therapeutics General Counsel Sells Shares to Cover Tax Obligations

Mike Ouimette, General Counsel of Pliant Therapeutics, sold 7,656 shares of common stock to cover withholding tax liabilities related to vesting stock units.

Summary

• On July 10, 2024, Mike Ouimette, the General Counsel of Pliant Therapeutics, sold 7,656 shares of the company's common stock.
• The sale was executed at a price of $11.56 per share.
• The transaction was a non-discretionary sale by the plan on behalf of the reporting person in a manner intended to satisfy the requirements of Rule 10b5-1.
• The sale was to cover withholding tax liability in connection with the vesting of previously granted performance-vested stock units.
• Following the transaction, Ouimette directly owns 94,044 shares of Pliant Therapeutics.
• The shares were sold at prices ranging from $10.785 to $12.58 between July 10, 2024 and July 11, 2024.

Sentiment

Score: 5

Explanation: This is a neutral event. The sale of shares is related to tax obligations and doesn't necessarily reflect a negative outlook on the company.

Industry Context

This is a routine Form 4 filing related to insider transactions. It is common for company executives to sell shares to cover tax obligations related to vesting equity.

Comparison to Industry Standards

• It's common practice for executives at publicly traded companies, such as Pliant Therapeutics, to utilize 10b5-1 trading plans to manage the sale of their shares.
• These plans, like the one used by Mike Ouimette, allow insiders to sell shares at predetermined times and prices, helping to avoid accusations of insider trading.
• Similar transactions are regularly seen at comparable biotech firms like Gilead Sciences or Biogen, where executives sell shares to cover tax liabilities or diversify their holdings.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the explanation provided mitigates this concern.

Key Dates